While Pfizer remains on track for an impressive $7.2 billion in cost cuts by the end of 2027, we think the market is more ...

Pharmaceutical major recorded a revenue jump to $14.65 billion, exceeding the market expectations. The company also raised ...

PFE posts strong Q2 results with earnings up 30% and revenues up 10% year over year, fueled by rising oncology sales and cost ...

Aug 5 - Pfizer (NYSE:PFE) heads into its Q2 earnings release amid growing investor caution. Analysts expect revenue around ...

Pfizer Inc displayed a robust performance in its Q2 2025 earnings call, with significant strides in revenue and research ...

Pfizer, the U.S.-based pharmaceutical giant, revealed its second-quarter financial results on Tuesday, showcasing a robust 10 ...

Pfizer's second-quarter 2025 results exceeded expectations with a 10% revenue growth and an adjusted EPS of $0.78.

Pfizer (PFE) stock is rising after the company reported strong second-quarter earnings and lifted its full-year forecast ...

Global pharmaceutical company Pfizer (NYSE:PFE) announced in Q2 CY2025, with sales up 10.3% year on year to $14.65 billion.

In an upward revision of its full-year guidance, Pfizer said it now expects adjusted earnings per share for 2025 to range between 2.90 dollars and 3.10 dollars, compared to its previous forecast of ...

Pfizer (NYSE:PFE) stock gains as the company surpasses Q2 2025 expectations with $14.7B revenue and raises its full-year ...